These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 16962494)
1. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Simons JW; Sacks N Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494 [TBL] [Abstract][Full Text] [Related]
2. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721 [TBL] [Abstract][Full Text] [Related]
5. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509 [TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045 [TBL] [Abstract][Full Text] [Related]
7. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Hege KM; Jooss K; Pardoll D Int Rev Immunol; 2006; 25(5-6):321-52. PubMed ID: 17169779 [TBL] [Abstract][Full Text] [Related]
11. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer. Lim M; Simons JW Curr Opin Mol Ther; 1999 Feb; 1(1):64-71. PubMed ID: 11249686 [No Abstract] [Full Text] [Related]
12. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutics in development for prostate cancer. Harzstark AL; Small EJ Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474 [TBL] [Abstract][Full Text] [Related]
14. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257 [TBL] [Abstract][Full Text] [Related]
15. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066 [TBL] [Abstract][Full Text] [Related]
16. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327 [TBL] [Abstract][Full Text] [Related]